<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[0, 4] Salmeterol plus fluticasone propionate<br>[5, 10] fluticasone propionate plus montelukast:<br>[76, 88] salmeterol plus fluticasone propionate (FP) (Seretide; SFC)<br>[89, 95] FP plus montelukast (FP/M)<br>[121, 124] SFC or FP/M<br>[207, 208] SFC<br>[220, 222] FP/M. FP/M<br>[232, 233] SFC<br>[267, 268] SFC.<br></td>
<td width=33%>
[0, 4] Salmeterol plus fluticasone propionate<br>[5, 10] fluticasone propionate plus montelukast:<br>[76, 88] salmeterol plus fluticasone propionate (FP) (Seretide; SFC)<br>[89, 95] FP plus montelukast (FP/M)<br>[119, 128] randomised to SFC or FP/M for 12 weeks.<br>[207, 208] SFC<br>[220, 222] FP/M. FP/M<br>[232, 233] SFC<br>[267, 268] SFC.<br></td>
<td width=33%>
[0, 10] Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast:<br>[75, 109] of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in<br>[119, 128] randomised to SFC or FP/M for 12 weeks.<br>[137, 150] , macrophage, lymphocyte, and epithelial cell levels in induced sputum.<br>[207, 208] SFC<br>[220, 222] FP/M. FP/M<br>[232, 233] SFC<br>[267, 268] SFC.<br></td>
</tr>
